The connection between metabolic control, length of illness and neuropathy in children and adolescents with T1 Diabetes Short title: Metabolic control and neuropathy in children with T1 Diabetes
DOI:
https://doi.org/10.5457/ams.v41i1.265Abstract
Background. Diabetic neuropathy is a clinical or sub-clinical disorder in type 1 diabetes mellitus (T1DM) in the absence of any other causes for peripheral neuropathy. Methods. This one-year study comprised 69 subjects, children and adolescents with T1DM. The metabolic control of the illness was assessed on the basis of the glycaemia, glycosylated haemoglobin, lipid status, blood pressure, body weight and height and body mass index of the subjects. The data from a questionnaire assessed the frequency of clinical signs of diabetic neuropathy. Results. The clinical manifestations of diabetic neuropathy were muscular weakness, cramps, paraesthesia, insensitivity to pain, vomiting, diarrhoea, urinary disorders. The subjects with neuropathy had glycaemia of 9.8±1.8 mmol/L and HbA1C 10.6 ± 2.2%, with statistically significantly increased triglyceride levels (t=1.8, p=0.04), systolic and diastolic blood pressure (t=5.4, p <0.001; t=6.4 p<0.001) and BMI (t=2.0, p=0.05). The subjects with T1DM>10 years had significantly more frequent pathological findings of the back of the eye (X2=3,2, p=0,02), with no statistically significant difference in albumin/creatinine (urine). The ROC curve with an analysis of age at the beginning of neuropathy was 11.7 years, with 55% sensitivity and 82% specificity. Conclusion. Our analysis suggests that there is a significant connection between the metabolic condition and the duration of the illness and the increased frequency of neuropathy in children and adolescents with T1DM. Aim. To test the hypothesis that metabolic control and length of illness are connected with an increased frequency of neuropathy in children and adolescents with T1DM.Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
